Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Hirotsugu Kenmotsu(Shizuoka Cancer Center), Kazushige Wakuda(Shizuoka Cancer Center), Keita Mori(Shizuoka Cancer Center), Terufumi Kato(Kanagawa Prefectural Hospital Organization), Shunichi Sugawara(Sendai Kousei Hospital), Keisuke Kirita(National Cancer Center Hospital East), Yasuto Yoneshima(Kyushu University), Koichi Azuma(Kurume University), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Shunsuke Teraoka(Wakayama Medical University), Takehito Shukuya(Juntendo University), Ken Masuda(Hiroshima City Asa Citizens Hospital), Hidetoshi Hayashi(Kindai University), Ryo Toyozawa(National Hospital Organization Kyushu Cancer Center), Satoru Miura(Niigata Cancer Center Hospital), Daichi Fujimoto(Kobe City Medical Center General Hospital), Kazuhiko Nakagawa(Kindai University), Nobuyuki Yamamoto(Wakayama Medical University), Toshiaki Takahashi(Shizuoka Cancer Center)
Cited by 156
Abstract
Related Papers
No related papers found
Powered by citation graph analysis